For example, ATG4B is highly expressed in lung cancer tissues (Wu et al., 2016b); targeting Atg4B inhibits autophagy and reduces tumor cell survival in chronic myeloid leukemia (Rothe et al., 2014); overexpression of the dominant negative mutant Atg4BC74A in prostate cancer inhibits cell proliferation and enhances chemotherapeutic drug sensitivity (Tran et al., 2013). This evidence concerns the gene ATG4B and prostate carcinoma.